Valiant LaboratoriesNSE:VALIANTLAB -0.06%51 Net Margin % is 1.91% as of Mar. 2026, which is 57% below its 10-year median of 4.43. GuruFocus rates NSE:VALIANTLAB with a GF Score™ of 51/100 and a GF Value™ of ₹103.25 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 956 Drug Manufacturers companies, Valiant Laboratories ranks worse than 67.99% on this metric.
The historical rank and industry rank for Valiant Laboratories's Net Margin % or its related term are showing as below:
NSE:VALIANTLAB'
s Net Margin % Range Over the Past 10 Years
Min: -1.65 Med: 4.43 Max: 16.78
Current: -1.38
NSE:VALIANTLAB's Net Margin % is ranked worse than 67.99% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs NSE:VALIANTLAB: -1.38
Valiant Laboratories (NSE:VALIANTLAB) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Valiant Laboratories Net Margin % Related Terms
Valiant Laboratories Net Margin % Historical Data
* Premium members only.
The historical data trend for Valiant Laboratories's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Valiant Laboratories's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valiant Laboratories Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Valiant Laboratories's Net Margin % distribution charts can be found below:
* The bar in red indicates where Valiant Laboratories's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Valiant Laboratories (NSE:VALIANTLAB) has a Net Margin % of 1.91% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Valiant Laboratories and its competitors. This is 57% below median its historical median of 4.43. According to the industry distribution chart, Valiant Laboratories ranks #650 out of 956 companies in the Drug Manufacturers industry, placing it in the top 68%.
Is Valiant Laboratories' Net Margin % too high?
Valiant Laboratories' current Net Margin % of 1.91% is 57% below median its 10-year median of 4.43. The Drug Manufacturers industry median Net Margin % is 5.56. Valiant Laboratories' value of 1.91% is 65.6% below this industry median. Based on the distribution chart, Valiant Laboratories ranks #650 out of 956 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Valiant Laboratories has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Valiant Laboratories' Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Valiant Laboratories ranks #650 out of 956 companies for Net Margin %. This places Valiant Laboratories in the lower half of its industry. The industry median Net Margin % is 5.56. Valiant Laboratories' value of 1.91% is 65.6% below this benchmark. While the company's 10-year median is 4.43 vs. the industry median of 5.56, Valiant Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Valiant Laboratories's current Net Margin % of 1.91% is 65.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Valiant Laboratories and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Valiant Laboratories's current Net Margin % is 1.91%, which is 57% below median its own 10-year median of 4.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valiant Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Valiant Laboratories (NSE:VALIANTLAB) is currently considered Possible Value Trap. The stock's GF Value™ is ₹103.25, compared to a current price of ₹68.00 — trading 34.1% below its estimated fair value. The current Net Margin % is 1.91%, which is 57% below median its 10-year median of 4.43 and 65.6% below the Drug Manufacturers industry median of 5.56. Valiant Laboratories' overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Valiant Laboratories (NSE:VALIANTLAB), the current Net Margin % is 1.91% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Valiant Laboratories (NSE:VALIANTLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Valiant Laboratories stock appears to be undervalued.
The current stock price of ₹68.00 is trading 34.1% below its estimated GF Value™ of ₹103.25.
GuruFocus considers Valiant Laboratories to be Possible Value Trap.
Key valuation signals for NSE:VALIANTLAB:
Net Margin %: 1.91% (57% below median its 10-year median of 4.43)
GF Value™: ₹103.25 vs. price of ₹68.00 (34.1% below fair value)
Industry Position: 65.6% below the Drug Manufacturers median (#650 of 956)
No single metric tells the full story. See the NSE:VALIANTLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Valiant Laboratories Ltd is an Active Pharmaceutical Ingredient (API)/Bulk Drug manufacturing company with having focus on manufacturing Paracetamol. Paracetamol is one of the widely used analgesics globally and is recommended as the first-line therapy in pain conditions by the World Health Organization. Paracetamol has several applications such as usage in the treatment of headaches, muscle aches, arthritis, backaches, toothaches, colds, and fever. It manufactures Paracetamol in various grades such as IP/BP/EP/USP, as per the pharmacopeia requirements of its customers.
51GF Score
Get the complete analysis for NSE:VALIANTLAB
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:VALIANTLAB has been successfully added to your 
